Clinical trials: Efavirenz
HIV Infections
Safety, Tolerability and Pharmacokinetics of Efavirenz in HIV-Infected Children
The primary purpose of this study is to find the dose of Efavirenz for young children. The safety and how the medication is tolerated will also be studied.
- Trial name
- NCT00364793
- Testing
- Efavirenz (EFV) + Didanosine (ddI) + Emtricitabine (FTC)
- Where
- 17 sites in Argentina, Colombia and 4 more
- Volunteers
- 56 people
- Sponsor
- Bristol-Myers Squibb
Acute HIV Infection
Pilot Study of Raltegravir/Truvada Versus Efavirenz/Truvada for Adults With Acute IV-1 Infection
This is a single-site, investigator-initiated, open-label, randomized/controlled clinical trial to compare the viral load response in plasma (and, in a subset of subjects, in gastrointestinal lymphoid tissue reservoirs) in…
- Trial name
- NCT00734344
- Testing
- Raltegravir, Efavirenz, Emtricitibine
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- University of Alabama at Birmingham
HIV-1 Infection
Compare the Efficacy and Safety of Raltegravir Versus Efavirenz Combination Therapy in Treatment-naïve HIV-1 Patients
A pilot study to compare the efficacy and safety of raltegravir-based versus efavirenz-based combination therapy in treatment-naïve patients with HIV-1 infection.
- Trial name
- NCT01989910
- Testing
- Raltegravir, Efavirenz
- Where
- Taiwan
- Volunteers
- 107 people
- Sponsor
- Taipei Veterans General Hospital, Taiwan
HIV Infection, HIV
A Clinical Trial Comparing the Tolerability of Etravirine to Efavirenz in Combination With 2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors in Treatment-naive HIV-1 Infected Patients
The purpose of this study is to compare the neuropsychiatric adverse event profiles of etravirine 400mg once daily versus efavirenz 600mg once daily, in combination with 2 N(t)RTIs, in approximately 150 treatment-naÃ-ve HIV-1…
- Conditions
- HIV Infection, HIV, Acquired Immunodeficiency Syndrome
- Trial name
- SENSE (NCT00903682)
- Testing
- etravirine (ETR, TMC125), efavirenz (EFV)
- Where
- 33 sites in Austria, Denmark and 9 more
- Volunteers
- 157 people
- Sponsor
- Janssen-Cilag International NV
Infection, Human Immunodeficiency Virus
A Dose Ranging Trial of GSK1349572 and 2 NRTI in HIV-1 Infected, Therapy Naive Subjects
This Phase IIb study in HIV-infected antiretroviral naive subjects will select an optimal once daily dose of GSK1349572 from a range of doses for future evaluation.
- Trial name
- ING112276 (NCT00951015)
- Testing
- GSK1349572, efavirenz
- Where
- 35 sites in United States, France and 4 more
- Volunteers
- 208 people
- Sponsor
- ViiV Healthcare
HIV Infections
A Study to Evaluate the Safety and Antiretroviral Activity of MK-0518 Versus Efavirenz in Treatment Naive HIV-Infected Patients, Each in Combination With TRUVADA (0518-021 EXT)
This study will investigate the safety and efficacy of MK-0518 versus efavirenz, in combination with TRUVADA, as a therapy for Human Immunodeficiency Virus (HIV)-infected patients not previously treated.
- Trial name
- NCT00369941
- Testing
- MK-0518, Comparator: efavirenz, Comparator: Truvada
- Volunteers
- 566 people
- Sponsor
- Merck Sharp & Dohme LLC
HIV Infections
Evaluating the Efficacy and Safety of Dolutegravir-Containing Versus Efavirenz-Containing Antiretroviral Therapy Regimens in HIV-1-Infected Pregnant Women and Their Infants
The purpose of this study was to compare the virologic efficacy and safety of three antiretroviral (ARV) regimens, dolutegravir plus emtricitabine/tenofovir alafenamide, dolutegravir plus emtricitabine/tenofovir disoproxil…
- Trial name
- VESTED (NCT03048422)
- Testing
- Dolutegravir, Emtricitabine/tenofovir alafenamide, Emtricitabine/tenofovir disoproxil fumarate
- Where
- 21 sites in United States, Botswana and 7 more
- Volunteers
- 643 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV-1-infection
B/F/TAF vs Atripla Double-Blind Switch Study in HIV-1 Infected Adults
Atripla (ATP: FTC/TDF/EFV) was the first single pill treatment for HIV and was the most prescribed first-line treatment from approximately 2008 to 2013 for people infected with HIV.
- Trial name
- NCT03532425
- Testing
- B/F/TAF, Atripla
- Where
- Canada
- Volunteers
- 28 people
- Sponsor
- University of Alberta
HIV
Effects of Switching Efavirenz to Raltegravir on Vascular Function and Bone Markers in HIV-infected Patients
Efavirenz, a commonly used HIV medication, may cause worsening vascular function and bone problems. The purpose of this study is to determine if switching efavirenz to raltegravir, a newer HIV medication, will improve vascular…
- Trial name
- NCT01270802
- Testing
- Tenofovir/emtricitabine, Tenofovir/emtricitabine/efavirenz, Raltegravir
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Indiana University
HIV
Virological and Immunological Safety of a Dose Reduction Strategy Antiretroviral Regimen With Efavirenz / Tenofovir / Emtricitabine
The main objective is to determine the feasibility of maintaining virologic suppression on standard plasma viral load by dose reduction of ATRIPLA ®.
- Trial name
- A-TRI-WEEK (NCT01778413)
- Testing
- ATRIPLA
- Where
- Spain
- Volunteers
- 61 people
- Sponsor
- Anna Cruceta
HIV Infections
FOTO: Five Consecutive Days on Treatment With Efavirenz, Tenofovir, and Emtricitabine Followed by Two Days Off Treatment Versus Continuous Treatment
For people with HIV who are currently taking specific medications (including Sustiva (efavirenz)) and have no detectable viral load, this study tracks how patients do if they take their medications for five days of the week…
- Trial name
- NCT00414635
- Testing
- Intermitent Dosing
- Where
- 7 sites in United States
- Volunteers
- 60 people
- Sponsor
- Community Research Initiative of New England
HIV Infections
Tenofovir Disoproxil Fumarate/Emtricitabine/Efavirenz Versus Combivir/Efavirenz in Antiretroviral-Naive HIV-1 Infected Subjects
The purpose of Study GS-01-934 was to assess the efficacy and safety of two simplified antiretroviral treatment (ART) regimens in ART-naive, human immunodeficiency virus, type 1 (HIV-1) infected participants.
- Trial name
- NCT00112047
- Testing
- Emtricitabine (FTC), Tenofovir Disoproxil Fumarate (TDF), Efavirenz (EFV)
- Where
- 5 sites in United States
- Volunteers
- 517 people
- Sponsor
- Gilead Sciences
HIV-1 Infection
Study to Evaluate the Safety and Efficacy of a Single Tablet Regimen of Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate Compared With a Single Tablet Regimen of Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naive Adults
The purpose of the study was to evaluate the safety and efficacy of the emtricitabine (FTC)/rilpivirine (RPV)/tenofovir disoproxil fumarate (TDF) single-tablet regimen (STR) compared with the efavirenz (EFV)/FTC/TDF STR in HIV-1…
- Trial name
- NCT01309243
- Testing
- FTC/RPV/TDF, EFV/FTC/TDF
- Where
- 151 sites in United States, Australia and 12 more
- Volunteers
- 799 people
- Sponsor
- Gilead Sciences
HIV-1 Infection
Study to Evaluate Switching From a Regimen Consisting of the Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate Single-Tablet Regimen (STR) to the Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate STR
The purpose of this Phase 2b study was to evaluate the efficacy and safety of the emtricitabine/rilpivirine/tenofovir disoproxil fumarate (FTC/RPV/TDF) STR, after switching from the efavirenz (EFV)/FTC/TDF STR at baseline, in…
- Trial name
- NCT01286740
- Testing
- FTC/RPV/TDF
- Where
- 18 sites in United States
- Volunteers
- 50 people
- Sponsor
- Gilead Sciences
HIV, HIV Infections
Sustiva Levels With Use of a Gel Capsule
We are studying if putting a gel capsule over a standard HIV drug changes the ability of the body to absorb the drug. This is important because we want to be able to study new HIV drugs against the most common drugs used today…
- Trial name
- NCT01087814
- Testing
- Efavirenz, Over-encapsulated efavirenz
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- University of Minnesota
Healthy Subjects, Drug-drug Interaction
A Study of the Effect of a Moderate CYP3A Inducer Efavirenz on Quizartinib Pharmacokinetics in Healthy Participants
This drug-drug interaction (DDI) study has been designed to investigate the effect of a moderate CYP3A inducer efavirenz on the pharmacokinetics of quizartinib and its major circulating active metabolite AC886.
- Conditions
- Healthy Subjects, Drug-drug Interaction, Pharmacokinetics, Quizartinib
- Trial name
- NCT04459598
- Testing
- Efavirenz, Quizartinib
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Daiichi Sankyo Co., Ltd.
HIV Infections
Safety and Effectiveness of Emtricitabine, Efavirenz, and Didanosine in HIV Infected Children Who Have Taken Few or No Anti-HIV Drugs
Treatment of HIV-infected patients involves combining drugs from different classes of anti-HIV drugs. One preferred regimen for adults is 2 nucleoside reverse transcriptase inhibitors (NRTIs) and 1 protease inhibitor (PI).
- Trial name
- NCT00016718
- Testing
- Didanosine (ddI), Efavirenz (EFV), Emtricitabine (FTC)
- Where
- 18 sites in United States, Puerto Rico
- Volunteers
- 43 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Healthy
Drug-Drug Interaction Study Between Fenofibric Acid and Efavirenz
Efavirenz is predominantly metabolized by cytochrome P450 (CYP) 2B6. Fenofibric Acid is an inhibitor of CYP 2B6. This study will evaluate the effect of multiple doses of fenofibric acid at steady-state on the pharmacokinetics of…
- Trial name
- NCT00960570
- Testing
- Efavirenz 600 mg, Fenofibric Acid
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Mutual Pharmaceutical Company, Inc.
Hyperlipidemia, HIV
Pharmacokinetic Study of Pitavastatin and Ritonavir-Boosted Darunavir or Efavirenz
The main goal of this study is to determine how taking efavirenz affects the levels of pitavastatin in the bloodstream when both drugs are taken together and to see how darunavir with ritonavir affects the levels of pitavastatin…
- Trial name
- NCT01695954
- Testing
- Pitavastatin, Darunavir, Ritonavir
- Where
- United States
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- NYU Langone Health
Hepatitis C, HIV
Part A: Drug Interaction Study of Sofosbuvir and Antiretroviral Therapy (ART) Combinations in HIV and Hepatitis C Virus (HCV) Co-infected Patients. Part B: Efficacy and Safety of Sofosbuvir for 12 Weeks in HIV/HCV Co-infected Patients.
This study consists of 2 parts, Part A and Part B. Part A, the Phase 1 drug interaction/early viral kinetic study, will evaluate the effect of selected antiretroviral therapies on the safety, viral kinetics, and pharmacokinetics…
- Trial name
- NCT01565889
- Testing
- SOF, EFV/FTC/TDF, EFV
- Where
- Puerto Rico
- Volunteers
- 52 people
- Sponsor
- Gilead Sciences